Twist Bioscience Corporation (TWST)
$
41.07
-0.51 (-1.24%)
Key metrics
Financial statements
Free cash flow per share
-1.2517
Market cap
2.5 Billion
Price to sales ratio
6.6827
Debt to equity
0.1598
Current ratio
3.6427
Income quality
0.6132
Average inventory
27.1 Million
ROE
-0.1682
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Twist Bioscience Corporation, a prominent synthetic biology company, specializes in the manufacture and sale of synthetic DNA-based products. The company's innovative DNA synthesis platform allows for the production of synthetic DNA by effectively writing DNA on a silicon chip. In addition to synthetic genes, Twist offers various products, including tools for sample preparation, antibody libraries aimed at drug discovery and development, and DNA utilized as a medium for digital data storage. The company's collaboration agreements with various organizations, such as Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., focus on the development of advanced sequencing tools. Furthermore, Twist has established a research collaboration with Boehringer Ingelheim International GmbH to leverage proprietary antibody libraries for discovering therapeutic antibodies across multiple targets. The company's stock is identified with the symbol 'TWST' in the market, and the net total of other income and expenses is $59,308,000.00 reflecting non-core financial activities. With a weighted average number of shares outstanding of 59,808,000.00 the company's equity reflects its shareholder base. The EBITDA is -$52,098,000.00 serving as a key indicator of the company's operational profitability, and the income before tax ratio is -0.20 demonstrating the pre-tax margin. In the current market, the stock is affordable at $27.89 making it appealing for budget-conscious investors. With an average trading volume of 1,438,626.00 the stock indicates moderate liquidity, which could attract a variety of investors. Additionally, the company maintains a mid-range market capitalization of $2,516,508,929.00 marking it as a steady performer in its field. Twist Bioscience Corporation is considered a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape. As it belongs to the Healthcare sector, the company continues to drive innovation and growth, aligning with the evolving needs of the synthetic biology market.
Is Twist Bioscience Corporation (TWST) a good investment?
Investing in Twist Bioscience Corporation (TWST) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Twist Bioscience Corporation (TWST)'s stock forecast?
Analysts predict Twist Bioscience Corporation stock to fluctuate between $23.30 (low) and $54.74 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Twist Bioscience Corporation's market capitalization?
As of 2026-01-30, Twist Bioscience Corporation's market cap is $2,516,508,929, based on 61,273,653 outstanding shares.
How does Twist Bioscience Corporation compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Twist Bioscience Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Twist Bioscience Corporation (TWST) stock?
To buy Twist Bioscience Corporation (TWST) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TWST. Place an order (Market, Limit, etc.).
What is the best time to invest in Twist Bioscience Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Twist Bioscience Corporation perform in the last earnings report?
Revenue: $376,572,000 | EPS: -$1.30 | Growth: -63.89%.
Where can I find Twist Bioscience Corporation's investor relations reports?
Visit https://www.twistbioscience.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Twist Bioscience Corporation?
You can explore historical data from here
What is the all-time high and low for Twist Bioscience Corporation stock?
All-time high: $139.99 (2021-11-05) | All-time low: $11.46 (2023-05-02).
What are the key trends affecting Twist Bioscience Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Twist Bioscience (TWST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
seekingalpha.com
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. If you currently own Twist stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about.
globenewswire.com
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders.
forbes.com
Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but significant drops like this often prompt a more challenging question: is this weakness merely temporary, or does it indicate more profound issues in the narrative?
seekingalpha.com
Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript
benzinga.com
Twist Bioscience Corporation (NASDAQ: TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.
zacks.com
Twist Bioscience (TWST) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.59 per share a year ago.
businesswire.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2025 earnings report and the investor presentatio.
benzinga.com
Twist Bioscience Corporation (NASDAQ: TWST) will release fourth-quarter earnings before the opening bell on Friday, Nov. 14.
See all news
